Cost assessment of health interventions and diseases
- PMID: 33148784
- PMCID: PMC7856133
- DOI: 10.1136/rmdopen-2020-001287
Cost assessment of health interventions and diseases
Abstract
Health resource use and identification of related costs are two essential steps in health economics assessment. The elicited costs will be balanced with health outcome improvement and enable the comparison of different diagnostic procedures or therapeutic strategies from a health economic point of view. The cost typology can be disentangled in three main components, that is, direct cost related to health resource use, indirect costs related to productivity loss and sometimes intangible costs (costs related to pain and suffering). These costs can be elicited from different perspectives depending on the general aim of the assessment: payer, societal perspective or patient perspective. Practically, the first step corresponds to the quantification of health resource use, that is, number of consultations, biological or imaging workups, hospitalisation, dispensed medication units or days on sick leave. It can be done by specific self-questionnaires or by access to insurance health databases. The second step is then to value each health resource use item, based on available public databases-either produced by insurance entities or statistics institute-providing the unit costs for each item. Importantly, substantial variability does exist in the costing exercise, requiring accepting a certain uncertainty around cost estimates. This can be taken into account by sensitivity analyses, which capture in what extent measurement error can impact cost assessment, depending on different hypotheses or assumptions. One essential element of health economic assessment is the identification of costs incurred by or associated with a specific health condition for a study on the economic burden of a disease-cost-of-illness study-or with a given diagnostic or therapeutic intervention in the context of health technology assessment in which these costs are compared with the alternative reference strategy-cost-effectiveness study.
Keywords: Economics; Epidemiology; Health services research.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Conflict of interest statement
Competing interests: BF has received research grants from AbbVie, Lilly, MSD and Pfizer, and consultancy fees from AbbVie, Amgen, Biogen, BMS, Celgene, Celltrion, Fresenius Kabi, Gilead, Janssen, Lilly, Medac, MSD, Mylan, NORDIC Pharma, Novartis, Pfizer, Roche, Sandoz, Sanofi-Genzyme, SOBI and UCB.
Figures
References
-
- Ruof J, Hulsemann JL, Stucki G. Evaluation of costs in rheumatic diseases: a literature review. Curr Opin Rheumatol 1999;11:104–9. - PubMed
-
- Merkesdal S, Ruof J, Huelsemann JL, et al. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. J Rheumatol 2001;28:657–61. - PubMed
-
- Gabriel S, Drummond M, Suarez-Almazor ME, et al. OMERACT 5 Economics Working Group: summary, recommendations, and research agenda. J Rheumatol 2001;28:670–3. - PubMed
-
- Merkesdal S, Ruof J, Schoffski O, et al. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001;44:528–34. - PubMed
-
- Drummond MF, Sculpher MJ, Torrance GW. Methods for economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 2005.
MeSH terms
LinkOut - more resources
Full Text Sources